|
Real-time Estimate
Cboe BZX
16:07:54 25/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 25.10 USD | +3.74% |
|
+3.27% | +52.06% |
| 12:57pm | B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating | MT |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| Market Cap | 3.87B 3.32B 3.1B 2.84B 5.35B 370B 5.41B 36.7B 14.27B 186B 14.52B 14.21B 615B | P/E 2026 * |
-10.7x | P/E 2027 * | -10.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3.16B 2.71B 2.53B 2.32B 4.37B 303B 4.42B 29.98B 11.66B 152B 11.86B 11.61B 503B | EV / Sales 2026 * |
51.9x | EV / Sales 2027 * | 24.1x |
| Free-Float |
90.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Denali Therapeutics Inc.
| 1 day | +3.82% | ||
| 1 week | +3.27% | ||
| Current month | +9.06% | ||
| 1 month | +6.51% | ||
| 3 months | +29.54% | ||
| 6 months | +12.63% | ||
| Current year | +52.06% |
| 1 week | 23.41 |  | 25.7 |
| 1 month | 22.63 | | 25.74 |
| Current year | 15.34 | | 27.3 |
| 1 year | 12.58 | | 27.3 |
| 3 years | 10.57 | | 33.33 |
| 5 years | 10.57 | | 56.8 |
| 10 years | 10.57 | | 93.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Schuth
DFI | Director of Finance/CFO | 52 | 30/04/2022 |
Ryan Watts
CEO | Chief Executive Officer | 50 | 31/07/2015 |
Peter Chin
CTO | Chief Tech/Sci/R&D Officer | 58 | 05/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ryan Watts
BRD | Director/Board Member | 50 | 28/02/2015 |
Jay Flatley
BRD | Director/Board Member | 73 | 31/03/2015 |
David Schenkein
BRD | Director/Board Member | 68 | 31/03/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 12/08/26 | Don | Founder | -32,220 | 0.0203% | ||
| 11/08/26 | Sell | Founder | -2,857 | 0.0018% | ||
| 03/06/26 | Free | Director | 25,634 | 0.0162% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.74% | +3.27% | +61.24% | +9.06% | 3.87B | |
| +3.31% | -3.53% | +71.28% | +104.57% | 69.06B | |
| +1.85% | +1.08% | +49.05% | +87.43% | 63.06B | |
| +2.83% | +24.68% | +10.06% | -1.68% | 28.34B | |
| +1.81% | -1.85% | -1.74% | +477.31% | 27.07B | |
| +7.41% | +13.08% | +58.57% | +17.04% | 25.45B | |
| +3.98% | +4.33% | +39.41% | -14.69% | 19.69B | |
| +1.02% | +5.67% | +273.94% | +420.34% | 19.19B | |
| +0.10% | +0.19% | +12.19% | +550.31% | 15.95B | |
| +2.71% | +5.55% | +47.94% | +154.98% | 13.52B | |
| Average | +2.86% | +3.49% | +62.19% | +180.47% | 28.52B | |
| Weighted average by Cap. | +2.81% | +2.90% | +59.10% | +156.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 60.84M 52.14M 48.78M 44.6M 84.16M 5.83B 85.05M 577M 224M 2.93B 228M 224M 9.68B | 129M 111M 104M 94.69M 179M 12.37B 181M 1.23B 477M 6.21B 485M 475M 20.55B |
| Net income | -452M -387M -362M -331M -625M -43.28B -632M -4.29B -1.67B -21.73B -1.7B -1.66B -71.91B | -453M -388M -363M -332M -627M -43.39B -633M -4.3B -1.67B -21.79B -1.7B -1.66B -72.09B |
| Net Debt | -708M -607M -568M -519M -980M -67.83B -990M -6.72B -2.61B -34.06B -2.66B -2.6B -113B | -749M -642M -600M -549M -1.04B -71.69B -1.05B -7.1B -2.76B -36B -2.81B -2.75B -119B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | US$25.12 | +3.80% | 169,949 |
| 24/08/26 | US$24.20 | -2.89% | 1,321,142 |
| 21/08/26 | US$24.92 | -0.12% | 680,993 |
| 20/08/26 | US$24.95 | -2.88% | 976,848 |
| 19/08/26 | US$25.69 | +5.68% | 1,150,287 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DNLI Stock
Select your edition
All financial news and data tailored to specific country editions
